Veeva Systems Inc.

By FY2020 (ended January 31, 2020), Veeva Systems generated $1.10B in total revenue — $896.3M (81%) from subscriptions and $207.8M (19%) from professional services — serving 861 life sciences customers. Subscription revenue retention rate was 121%, indicating strong expansion within the existing base. Subscription gross margins were 85%. Veeva had established itself as the dominant CRM for pharmaceutical and biotech sales forces (built on Salesforce's platform) and was expanding into R&D applications via its proprietary Vault platform for clinical, regulatory, quality, and safety workflows. The key question: could Veeva's regulatory-complexity-driven switching costs sustain near-permanent customer retention as the company expanded its product suite and migrated off the Salesforce platform?

Veeva deepened its switching cost moat through three reinforcing strategies: (1) Expanded the Vault platform across the entire drug lifecycle — Clinical (EDC, CTMS, eTMF), Regulatory (submissions, registrations), Quality (QMS, document control), and Safety (pharmacovigilance). Each additional Vault application created new data dependencies and validated-system integrations that compounded switching costs. (2) Built Veeva Data Cloud (OpenData for HCP/HCO reference data, Link for patient data, Compass for prescription claims, Crossix for patient analytics), adding proprietary data assets that became embedded in customer workflows. (3) Began migrating commercial CRM from Salesforce to its proprietary Vault CRM platform — a multi-year transition (Salesforce agreement expires September 2025, wind-down through 2030) that, once complete, will deepen platform lock-in by eliminating dependency on a third-party platform. (4) Expanded customer base from 861 to 1,477, with increasing multi-product adoption across both Commercial Solutions (730 customers) and R&D Solutions (1,125 customers).

Revenue grew from $1.10B (FY2020) to $2.75B (FY2025), a 149% increase. Subscription revenue grew from $896.3M to $2.29B (155% increase), with subscription gross margins holding at 85-86% throughout. Customer count grew from 861 to 1,477. Subscription retention rate sustained above 119% when last disclosed (FY2022). GAAP operating margin recovered from 25.9% (FY2020) to 25.2% (FY2025) after a temporary dip to 18.2% (FY2024) during heavy R&D investment in the Vault CRM platform build. Professional services revenue plateaued at $462M (FY2024-FY2025), confirming the subscription-centric model. Top 10 customers represented 28% of revenue, demonstrating healthy concentration in an industry with a finite number of large pharma companies.